enqubio-cro.bsky.social
banner
enqubio-cro.bsky.social
enqubio-cro.bsky.social
@enqubio-cro.bsky.social
What makes an orthotopic bladder cancer model reliable enough to inform a study?
Join us for a live walkthrough of data behind our MB49-Luc model, including tumor take, longitudinal imaging, immune context, and more!

Free live webinar.
🗓 Tuesday, June 30 · 10 AM PDT
Register: ow.ly/pQkk50Z9bz2
June 25, 2026 at 6:38 PM
We are delighted to join our partners at Bruker for a webinar. Melanie He will be presenting on - Advancing Bladder Cancer Research with Human-centric, Immune-Competent Orthrotopic Models.

Register to join! ow.ly/pQkk50Z9bz2
June 12, 2026 at 10:17 PM
EnquBio - San Diego based CRO is hiring!

We're excited to announce four open positions at EnquBio as we continue to expand our preclinical drug discovery capabilities in San Diego.
- Sr. Scientist
- Scientist I/II
- Head of Pharmacology
- Head of Assay & Screening
May 15, 2026 at 10:32 PM
We’re presenting at AACR this week in San Diego. Our team developed an immune-competent, durable MB49-Luc orthotopic bladder cancer model designed to overcome two of the biggest challenges in preclinical NMIBC research: low tumor take rates and limited in-life study duration.
April 14, 2026 at 12:42 AM
EnquBio will be at the American Association for Cancer Research 2026 (April 17–22) - find us at Booth #4358 Stop by to connect with our scientists and learn how EnquBio's drug R&D services can support your programs with our integrated services & solutions.
April 14, 2026 at 12:42 AM